Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Telomerase technology company reports Q2 loss of $8.9 million
September 8th, 2004
Geron Corp. (GERN) reported financial results for the three and six months ended June 30, 2004. For the second quarter of 2004, the company reported a net loss of $8.9 million or $0.20 per share compared to $9.3 million or $0.32 per share in the second quarter of 2003. Net loss for the first six months of 2004 was $60.6 million or $1.41 per share compared to $17.2 million or $0.63 per share for the same period in 2003. Revenues for the second quarter of 2004 were $366,000 compared to $285,000 for the comparable period in 2003. Revenues for the second quarter of 2004 included royalty revenues under license agreements with companies for sales of...
Source: Vaccine Weekly (2004-09-08)
|
